SCHEMBL721530

SCHEMBL721530

COc1cc(-c2cc3nccc(-c4cccc(OCCN)c4)c3o2)cc(OC)c1OC

nearest known ligand 0.47

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
PDE4C Q08493 3/20 0.47
FYN P06241 6/20 0.43
RPS6KA3 P51812 1/20 0.40
JAK2 O60674 3/20 0.40
JAK1 P23458 3/20 0.40
TYK2 P29597 2/20 0.40
JAK3 P52333 1/20 0.40
ADORA2A P29274 1/20 0.39
HDAC1 Q13547 2/20 0.37
HDAC2 Q92769 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL723374 0.87 PDE4C (0.39) PDE4CFYNADORA2A
SCHEMBL15210374 0.85 CYP1B1 (0.38) PDE4CFYN
SCHEMBL723918 0.85 PDE4C (0.46) PDE4CFYNJAK2JAK1TYK2
SCHEMBL722497 0.85 PDE4C (0.47) PDE4CFYNJAK2JAK1TYK2
SCHEMBL10267310 0.84 PDE4C (0.44) PDE4CJAK2JAK1TYK2JAK3
SCHEMBL10267650 0.83 FYN (0.54) PDE4CFYNJAK2JAK1TYK2
SCHEMBL721632 0.83 PDE4C (0.41) PDE4CFYNADORA2A
SCHEMBL723760 0.82 PDE4C (0.43) PDE4CFYNJAK2JAK1TYK2
SCHEMBL16638609 0.82 PDE4C (0.50) PDE4CFYNJAK2JAK1TYK2
SCHEMBL722839 0.82 PDE4C (0.51) PDE4CFYNJAK2JAK1TYK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2609100-B1 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2015-06-24 EP claimed
EP-2609100-B1 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2015-06-24 EP disclosed
EP-2609100-B1 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2015-06-24 EP disclosed
US-9006440-B2 Furopyridine derivatives MERCK PATENT GMBH (DE) 2015-04-14 US disclosed
US-9006440-B2 Furopyridine derivatives MERCK PATENT GMBH (DE) 2015-04-14 US disclosed
US-9006440-B2 Furopyridine derivatives MERCK PATENT GMBH (DE) 2015-04-14 US disclosed
US-20130225569-A1 FUROPYRIDINE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2013-08-29 US disclosed
US-20130225569-A1 FUROPYRIDINE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2013-08-29 US disclosed
EP-2609100-A2 FUROPYRIDINE DERIVATIVES Merck Patent GmbH (DE) 2013-07-03 EP disclosed
WO-2012025187-A2 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2012-03-01 WO disclosed
WO-2012025187-A2 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2012-03-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130225569-A1 FUROPYRIDINE DERIVATIVES SYK, FCGRT, SSB PDE4C 2858/4885FYN 33/4885RPS6KA3 482/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.